Opiant Pharmaceuticals

News

FDA clears nasal opioid reversal drug, lifting Indivior

The FDA has approved a new intranasal therapy for treating opioid overdose developed by Opiant Pharma, giving a boost to its new UK owner Indivior.

News

Indivior boosts addiction drug business with $145m Opiant de...

UK-based pharma Indivior has agreed a takeover deal with Opiant Pharma that consolidates its position in the addiction treatment category with a new intranasal therapy, due to be filed with

News

RNAi biotech City hauls in $200m in upsized IPO

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks